Eli Lilly forges on with PhIII evacetrapib trial; Biogen inks Parkinson's discovery pact; Soon-Shiong's NantKwest heads for IPO;

@FierceBiotech: Allergan bags NMDA depression drugs in $560M-plus Naurex buyout. News | Follow @FierceBiotech

@JohnCFierce: The China stock landslide is back on. More from Reuters | Follow @JohnCFierce

@DamianFierce: I kinda forgot this hadn't already happened, tbh. Aegerion release/Article | Follow @DamianFierce

> Eli Lilly ($LLY) says that it will push ahead to the end on its Phase III study of evacetrapib, a CETP inhibitor that hopes to succeed where other giants have failed. Lilly says that the ACCELERATE study data monitoring committee recommended continuing the study following a futility analysis. The last patient visit in the study is expected in July 2016. Investigators recruited roughly 12,000 patients for this trial. Release

> Three days after falling off a cliff on Wall Street, Biogen ($BIIB) is back with a discovery deal with the Parkinson's Institute and Clinical Center. Release

> Patrick Soon-Shiong's NantKwest is slated to price its IPO shares these evening. The company designed the IPO to raise about $150 million. If all goes as planned, the company will have a $2.2 billion market cap. Story

> Brisbane, CA-based Aimmune Therapeutics set a range of $14 to $16 a share on its IPO, with plans to sell 8.3 million shares. Story

> Germany's leon nanodrugs raised €18.5 million ($20.5 million) in Series A cash to advance its efforts to reformulate small-molecule and protein-based therapeutics using its in-house platform. More

> Samsung's biosimilars joint venture is planning to go public in the U.S. next year, Reuters reports. News

Medical Device News

@FierceMedDev: ICYMI: Oxford Performance Materials gets FDA nod for 3-D printed spinal implant. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Shire CEO: We're prepared to wait for the right deal. Article | Follow @EmilyWFierce

> Varian signs $124M deal with U.K.'s NHS for ProBeam cancer therapy. News

> Sorin stock plummets as Italian feds seek to block its merger with Cyberonics. Story

> Docs dole out recs for reducing fetal ultrasound procedures in the U.S. More

Pharma News

@FiercePharma: Harvard scientists link pesticides with bee losses. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Lupin lands its first US manufacturing site with $880M deal for GAVIS, 6-year-old NJ firm. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: UnitedHealth uses newfound scale to negotiate pay-for-performance deals. Article | Follow @CarlyHFierce

> Amgen wins new myeloma nod for blockbuster hopeful Kyprolis. News

> AstraZeneca snags $300M from Sanofi for rare cancer med amid cash-generating deal spree. Story

> Forget Mylan: Teva inks $40B-plus pact for Allergan's generics biz. Article

Animal Health News

> Animal health drives double-digit growth at Abaxis. Report

> Harvard scientists link pesticides with bee losses. Item

> H.J. Baker breaks ground on multimillion-dollar facility near KC animal health corridor. More

> USDA speeds development of bird flu vaccine as fears of revived virus mount. Article

> Aratana predicts full launch of two lymphoma drugs for dogs in late 2016. Story

Biotech IT News

> SynBio startup Ginkgo Bioworks lands $45M to fuel push into pharma. More

> PCORI board signs off on $142.5M investment to scale up health data network. Story

> BGI CEO steps down to escalate interest in artificial intelligence. Article

> Deep Genomics sets up shop to marry deep learning and genomics. Item

> Oxford Nanopore raises $109M ahead of key period for its sequencing technology. Report

Pharma Marketing News

> Sanofi draws a $14,600 line in the sand for Praluent payer fight. Report

> Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points. Story

> Will marketing make the difference in approval of Sprout's 'pink pill' for women? News

> J&J's Stelara may be under fire in psoriasis, but it's positioned to score elsewhere. More

> I'll prescribe it if you do: Prescribers susceptible to peer pressure, study finds. Report